You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Novel technologies to remove obscuring blood from fine needle aspiration biopsies

    SBC: AFFINERGY, LLC            Topic: NIGMS

    SUMMARY ABSTRACT Fine needle aspirationFNAcytology is the standard technique for evaluating thyroid nodulesHemorrhaging is common during the procedurehoweverleading to an aspirate that is significantly diluted by bloodSubsequent slide preparations are often suboptimalresulting in nondiagnostic outcomes that necessitate additional testing or diagnostic surgeryIn factquality is so unpredictable that ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. APPSPIRE: expanding the reach of an innovative tobacco control program for youth

    SBC: Radiant Creative Group, LLC            Topic: NIDA

    DESCRIPTIONprovided by applicantMobile phone technology offers a variety of opportunities for innovative approaches to health communication and interventionThese opportunities have been amplified by the emergence of next generation smartphone devices that are capable of rich multimedia and sophisticated interactivitySmartphone based programs can be integrated seamlessly into a userandapos s daily ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Using game mechanics to improve outcomes among stem cell transplant survivors

    SBC: Radiant Creative Group, LLC            Topic: NCI

    DESCRIPTION provided by applicant Adolescent and young adult AYA hematopoietic stem cell transplantation HSCT patients face a variety of well documented physical and emotional challenges In addition to undergoing a life threatening procedure that involves an intense treatment regimen and lengthy hospital stay these patients face a protracted month recovery period marked by numerous phy ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Novel and Kidney Selective AMPK Activators to Treat Polycystic Kidney Disease

    SBC: NOVATARG, INC.            Topic: 400

    DESCRIPTION provided by applicant Autosomal dominant polycystic kidney disease ADPKD is characterized by the presence of innumerous fluid filled cysts that progressively enlarge leading nephron loss and the progressive decline in renal function Aberrant proliferation of the cyst lining epithelial cells and the accumulation of fluid within the cysts du to Cl dependent fluid secretion are res ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Air Barrier System for the Prevention of Prosthesis-related Infections

    SBC: NIMBIC SYSTEMS, INC.            Topic: 300

    DESCRIPTIONprovided by applicantThis project is an evaluation of a novel devicethe Air Barrier SystemABSto reduce the risk of prosthesisrelated surgical site infection in a multi center clinical trialThe ABS shields surgical incisions intra operatively by creating a field of high purity air surrounding an incision that prevents airborne microorganisms from entering the incisionPreliminary findings ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma

    SBC: Annias Immunotherapeutics, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Malignant primary brain tumors represent the most frequent cause of cancer death in children and young adults and account for more deaths than cancer of the kidney or melanoma Glioblastoma GBM is uniformly lethal and current therapy is non specific and produces a median overall survival of andlt months In contrast immunotherapeutic approaches are exq ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Medical Images HTML and Clinical Trial Remote Collaboration

    SBC: HEART IMAGING TECHNOLOGIES, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Medical drugs and devices are regulated by the U S Food and Drug Administration FDA based on data from multicenter clinical trials In U S spending on clinical trials was approximately $ billion Over the past decade the efficiency of clinical trials has been improved by electronic data capture EDC systems whose use has increased from to ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Small molecules as antibiotic potentiating agents against multi-drug resistant Gram-negative infections

    SBC: AGILE SCIENCES, INC.            Topic: R

    DESCRIPTION provided by applicant Antibiotic resistance has been declared one of the three greatest threats to human health by the World Health Organization Infections caused by multi drug resistant MDR bacterial pathogens create substantial health and economic impacts on society due to the lack of effective therapeutic options created by the rapid acquisition of resistance and stagnant anti ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Improving the Host Response to Implantable Glucose Sensors via Nitric Oxide Release

    SBC: CLINICAL SENSORS, INC.            Topic: 200

    DESCRIPTION provided by applicant Diabetes mellitus is a metabolic disorder afflicting more than million Americans This disease manifests itself with abnormal blood glucose levels that lead to other significant health conditions including kidney failure nerve damage blindness heart attack and stroke For more than million diabetics using insulin to control hyperglycemia frequent moni ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL an Innate Immune Stimulant

    SBC: PULMOTECT, INC            Topic: NHLBI

    Pulmotect Inc was founded in to translate discoveries that induce innate immune resistance in the lung into therapeutics that will provide protection from inhaled pathogens Our technology platform is a direct result of basic research by our founders on the mechanisms of microbial resistance in the lung epithelium We have developed an inhaled therapeutic PUL that provides immediate p ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government